Open AccessSafety of single-dose nevirapine for prevention of vertical transmission of human immunodeficiency virus infection
Author(s) -
Mangala Bhaskar Murthy,
Bhaskar Krishnamurthy
Publication year - 2011
Publication title -
indian journal of pharmacology/the indian journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.286
H-Index - 59
eISSN - 1998-3751
pISSN - 0253-7613
DOI - 10.4103/0253-7613.77372
Subject(s) - nevirapine , medicine , adverse effect , vomiting , transmission (telecommunications) , human immunodeficiency virus (hiv) , pediatrics , nausea , obstetrics , virology , pharmacology , viral load , antiretroviral therapy , electrical engineering , engineering
Nevirapine administered as a single dose each to the mother and child within 72 h after birth is used to prevent vertical transmission of human immunodeficiency virus (HIV) under the prevention of parent to child transmission of HIV program (PPTCT). The efficacy of nevirapine in this regard has been proved beyond doubt, but there are unresolved questions about its safety. Hence, the primary objective of this study was to evaluate the safety of this regime.